The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Could Sirtuin Activities Modify ALS Onset and Progression?
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a complex etiology. Sirtuins have been implicated as disease-modifying factors in several neurological disorders, and in the past decade, attempts have been made to check if manipulating Sirtuin activities and levels could confer benefit in terms of neuroprotection and survival in ALS models. The efforts have largely focused on mutant SOD1, and while limited in scope, the results were largely positive. Here, the body of work linking Sirtuins with ALS is reviewed, with discussions on how Sirtuins and their activities may impact on the major etiological mechanisms of ALS. Moving forward, it is important that the potentially beneficial effect of Sirtuins in ALS disease onset and progression are assessed in ALS models with TDP-43, FUS, and C9orf72 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“treatment with SIRT1 activators, including resveratrol, ameliorates the disease progress in ALS animal models”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Tang, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Das, S., Mitrovsky, G., Vasanthi, H. R., & Das, D. K. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/345105 · Cited by 173
RetractedSong, L., Chen, L., Zhang, X., Li, J., & Le, W. (2014) · BioMed Research International · doi:10.1155/2014/483501 · Cited by 73
RetractedRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Cited by
Sorted by citations
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W. Q., Huang, C., Huber, P., Zhou, X., Li, C. L., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,147
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790
Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders
Salvadores, N., Sanhueza, M., Manque, P., & Court, F. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00451 · Cited by 182
Jurcău, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111847 · Cited by 152
Obrador, E., Palmer, R. S., López‐Blanch, R., Jihad-Jebbar, A., Vallés, S. L., & Estrela, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126352 · Cited by 104
Garcia Morato, J., Hans, F., von Zweydorf, F., Feederle, R., Elsässer, S. J., Skodras, A. A., Gloeckner, C. J., Buratti, E., Neumann, M., & Kahle, P. J. (2022) · Nature Communications · doi:10.1038/s41467-022-28822-7 · Cited by 94
de la Rubia, J. E., Drehmer, E., Platero, J. L., Benlloch, M., Caplliure-Llopis, J., Villaron-Casales, C., de Bernardo, N., AlarcÓn, J., Fuente, C., Carrera, S., et al. (2019) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2018.1536152 · Cited by 92
Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review
Carrera‐Juliá, S., Moreno, M. L., Barrios, C., Ortí, J. E. D. L. R., & Drehmer, E. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00063 · Cited by 87
Gilmour, B. C., Gudmundsrud, R., Frank, J., Hov, A., Lautrup, S., Aman, Y., Røsjø, H. R., Brenner, C., Ziegler, M., Tysnes, O., et al. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111208 · Cited by 44
Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis
Klingl, Y. E., Pakravan, D., & Bosch, L. V. D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15217 · Cited by 33
Molecular hallmarks of ageing in amyotrophic lateral sclerosis
Jagaraj, C. J., Shadfar, S., Kashani, S. A., Saravanabavan, S., Farzana, F., & Atkin, J. D. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05164-9 · Cited by 39
Bond, L., Bowen, G., Mertens, B., Denson, K., Jordan, K., Vidakovic, B., & Mitchell, C. S. (2020) · Behavioral Sciences · doi:10.3390/bs10010033 · Cited by 27
Sirtuins as Modifiers of Huntington's Disease (HD) Pathology
Neo, S. H., & Tang, B. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.013 · Cited by 25
Self-citationMetabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases
Lanznaster, D., Dingeo, G., Samey, R. A., Emond, P., & Blasco, H. (2022) · Metabolites · doi:10.3390/metabo12090864 · Cited by 12
Asano, T., Nakamura, H., Kawamoto, Y., Tada, M., Kimura, Y., Takano, H., Yao, R., Saito, H., Ikeda, T., Komiya, H., et al. (2022) · eNeuro · doi:10.1523/eneuro.0133-22.2022 · Cited by 12
The Scientific and Therapeutic Rationale for Off‐Label Treatments in Amyotrophic Lateral Sclerosis
Bedlack, R., Li, X., Evangelista, B., Panzetta, M. E., Kwan, J. Y., Gittings, L. M., & Sattler, R. (2024) · Annals of Neurology · doi:10.1002/ana.27126 · Cited by 9
Chen, C., Wang, T., Gao, T., Chen, Y.-L., Lu, Y., & Zhang, W. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111114 · Cited by 7
Amyotrophic lateral sclerosis disease modifying therapeutics: a cell biological perspective
Tang, B. L. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.202943 · Cited by 6
Self-citationEpplen, A. S. C., Rothöft, M., Stahlke, S., Theiß, C., & Matschke, V. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02415-5 · Cited by 5
The Epigenetics of Alzheimer's and Other Neurodegenerative Disorders
Coppedè, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812215-0.00010-8 · Cited by 5
ALSUntangled 42: Elysium health’s “basis”
Bedlack, R., & The ALSUntangled Group (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2017.1373978 · Cited by 3
Boosting Brain Clean-Up: Can Targeting UPS Genes Offer Neuroprotection?
Mannan, A., Sharma, A., & Singh, T. G. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05263-z · Cited by 2
NAMPT deficiency triggers dopaminergic neurodegeneration in the substantia nigra of mousePreprint
Chen, C., Gao, T., Wang, T., Chen, Y.-L., Lu, Y., & Zhang, W. (2024) · Research Square · doi:10.21203/rs.3.rs-3993436/v1
Condorelli, G. A., Iozzia, A., Bonifacio, D., & Pelin, A.-M. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04770-2
Metadata
- Authors
- Tang, B. L.
- Affiliations
- National University of Singapore (SG)
- Corresponding author
- Tang, Bor Luen
- ORCID
- Tang, Bor Luen
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2016-12-10
- Volume
- 37
- Issue
- 7
- Pages
- 1147-1160
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11482121
- OpenAlex
- W2560651871
- Cited by
- 24
- References
- 201
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 4
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National University of Singapore (C-183-000-102-091)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- amyotrophic lateral sclerosis, sirtuins, disease-modifying therapy, neuroprotection, SOD1 mutations, TDP-43, FUS, C9orf72
- MeSH terms
- Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Humans, Motor Neurons, Disease Progression, Sirtuins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
